HNSPF (Hansoh Pharmaceutical Group Co) Tariff Resilience Score: 4/10 (As of Jul. 07, 2026)


HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
91 GF Score
Price $3.83
GF Value $3.11
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Tariff Resilience Score?

Hansoh Pharmaceutical Group Co HNSPF 91 Tariff Resilience Score is 4 as of Jul. 07, 2026. GuruFocus rates HNSPF with a GF Score™ of 91/100 and a GF Value™ of $3.11 (Modestly Overvalued). Among 1,030 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 79.71% on this metric.

Hansoh Pharmaceutical Group Co has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Hansoh Pharmaceutical Group Co has Hansoh Pharmaceutical relies on global supply chains for raw materials and exports to various markets. Tariffs on pharmaceuticals or raw materials could impact costs. Mitigation includes diversifying suppliers and leveraging pricing power in key markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Hansoh Pharmaceutical Group Co might have Average Resilient.

Hansoh Pharmaceutical Group Co  (OTCPK:HNSPF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Hansoh Pharmaceutical Group Co Tariff Resilience Score Related Terms

HNSPF vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansoh Pharmaceutical Group Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Tariff Resilience Score falls into.


HNSPF
91GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Tariff Resilience Score of 4 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #209 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Hansoh Pharmaceutical Group Co's Tariff Resilience Score too high?
Hansoh Pharmaceutical Group Co's current Tariff Resilience Score is 4. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #209 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #209 out of 1030 companies for Tariff Resilience Score. This places Hansoh Pharmaceutical Group Co in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Hansoh Pharmaceutical Group Co's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.11, compared to a current price of $3.83 — trading 23% above its estimated fair value. The current Tariff Resilience Score is 4. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Tariff Resilience Score is 4 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 23% above its estimated GF Value™ of $3.11. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for HNSPF:

  • Tariff Resilience Score: 4
  • GF Value™: $3.11 vs. price of $3.83 (23% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score

Get the complete analysis for HNSPF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.11
GF Value